UC Berkeley’s Groundbreaking Study on Psilocybin

The UC Berkeley Center for the Science of Psychedelics has embarked on an unprecedented study to explore why psilocybin, a psychoactive compound found in certain mushrooms, alters visual perception in humans.

This investigation represents the university’s first human trials involving a Schedule I substance, classified by the federal government as having no accepted medical use.

Psilocybin, commonly known as “shrooms” or “magic mushrooms,” can significantly distort users’ sense of time, mood, and reality, often causing hallucinations.

Read more

Psilocybin for Anorexia

A recent study has shed light on the potential of psilocybin, the active compound in magic mushrooms, as a promising treatment for anorexia nervosa (AN).

This psychiatric disorder, known for its high mortality rate, has long been a challenging condition to treat effectively.

The research, conducted at Monash University, revealed that psilocybin could improve cognitive flexibility and help maintain body weight in an animal model of AN.

Read more

Serotonin Toxicity, Psilocybin and Anti-depressants

In a case report published in the journal Primary Care Companion to Central Nervous System Disorders, three Penn State clinicians describe a patient who experienced serotonin toxicity after combining antidepressants and anti-anxiety medications and psilocybin.

Serotonin toxicity, or serotonin syndrome, occurs when high levels of serotonin build up on the body; the condition can be fatal. 

Read more